BLOG
Needle-Free Delivery Explained: What Buccal Research Is Exploring
Free delivery is an active area of scientific research. One question researchers are exploring is whether some programs can be delivered through the tissues inside the mouth instead of being swallowed or injected.
This approach is often described as buccal delivery. It is also part of the broader field of oral transmucosal delivery, which means moving a substance across the mucous membranes of the mouth.
At VIP New Life, our goal is to help you understand the science clearly. We provide education and research information, not treatment recommendations. In this article, we will explain what buccal delivery means, why stability matters, and why a dissolving strip is not automatically the same as effective absorption.
> Research Use Only: Applicable VIP New Life research products referenced in this article are intended strictly for laboratory research purposes only. They are not intended for human consumption or for the diagnosis, treatment, cure, or prevention of any disease.
What Does Buccal Delivery Mean?
The word buccal refers to the inside lining of the cheek. Buccal delivery means placing a formulation near this tissue so that a research compound may dissolve and potentially move across the oral mucosa.
The oral mucosa is the soft tissue lining inside the mouth. It includes areas such as the inner cheeks, lips, gums, floor of the mouth, and the area beneath the tongue. Different parts of the mouth have different tissue structures and absorption characteristics.
Buccal delivery is different from simply eating or swallowing a product. With swallowed delivery, the material travels through the digestive system. With buccal delivery, researchers are investigating whether part of the material can move across the tissue in the mouth before it is swallowed.
The tissue contains blood vessels beneath its surface. This is one reason the oral mucosa has attracted interest as a possible delivery route. However, the presence of blood vessels does not mean that it will cross the tissue effectively.
Swallowing Is Not the Same as Buccal Absorption
It is easy to assume that anything placed in the mouth will be absorbed through the mouth. That is not necessarily the case.
If a dissolved product is swallowed with saliva, it enters the gastrointestinal tract. Once there, it may encounter:
- Strong stomach acid.
- Digestive enzymes.
- Enzymes in the small intestine.
- Mucus and epithelial barriers.
It is a chain of amino acids. Many programs are structurally delicate. Their biological activity depends on the shape and arrangement of that chain. If the chain is broken apart or changes shape, the original molecule may no longer remain intact.
Buccal absorption refers to a different pathway. In a successful buccal delivery system, the research question is whether it can remain sufficiently stable in the mouth, contact the mucosal tissue, move through the tissue barrier, and reach the circulation in an intact or appropriately preserved form.
That is a much more specific process than dissolving and swallowing.
Why Stomach Acid and Digestive Enzymes Matter
The digestive system is designed to break down proteins. This is useful when digesting food, but it creates a challenge for free delivery research.
In the stomach, acid and enzymes such as pepsin begin breaking proteins into smaller fragments. Further along the digestive tract, pancreatic and intestinal enzymes continue this process. These enzymes act on bonds, which connect amino acids together.
For research, this breakdown may reduce the amount of intact material available for absorption. It may be present in a capsule, tablet, or liquid, but that does not mean the original structure will remain unchanged after passing through digestion.
Research on oral delivery has identified gastrointestinal instability and limited membrane permeability as two major barriers. In simple terms, it may be broken down before it can cross the intestinal lining, and the molecules that remain may have difficulty crossing that barrier.
Buccal delivery is being explored partly because it can reduce exposure to the stomach and small intestine. However, avoiding the digestive tract does not remove every challenge. The oral cavity has its own saliva, mucus, enzymes, tissue barriers, and physical movement.
Why Dissolving in the Mouth Does Not Automatically Mean Effective Delivery
A dissolving strip can disappear quickly. That only tells us that the material has entered the saliva or moisture in the mouth. It does not by itself demonstrate that it has crossed the mucosal tissue.
Researchers must consider several separate steps:
- Dissolution: Does the formulation dissolve in the oral environment?
- Stability: Does it remain structurally intact while it dissolves?
- Contact: Does the dissolved material stay near the intended tissue long enough?
- Permeation: Can it move through the mucosal barrier?
- Exposure: Can researchers measure the amount and form of material that reaches circulation?
These questions are connected, but they are not interchangeable.
A product can dissolve rapidly and still have limited tissue movement. It can remain on the tissue and still fail to preserve it. It can contain a stable it and still face a barrier that restricts movement through the mucosa.
This is why research into buccal delivery looks beyond convenience or appearance. The formulation must be evaluated as a complete delivery system.
Stabilization Is an Important Research Question
The programs may be sensitive to moisture, temperature, pH changes, physical stress, and interactions with other ingredients. They may also change shape or form aggregates, where individual molecules join together.
Stabilization means designing a formulation environment that helps protect the structure during manufacturing, handling, dissolution, and contact with the oral tissue.
In research systems, stabilization may involve a protective matrix or other formulation components. The goal is not simply to keep the strip intact. The goal is to understand whether the product remains in a suitable form during the delivery process.
VIP New Life’s educational materials describe InstaRelease® as a platform designed for orally dissolving strips and mucosal delivery research. That description refers to the delivery platform design, not proof of absorption or bioavailability for any specific product. If the term bioavailability is used, it simply means how much of a substance reaches measurable circulation in a form researchers can detect and evaluate. Each product and formulation still requires its own testing.
Published research also shows that free delivery systems must be tested for stability, release, tissue interaction, and permeation. Results from one molecule or one formulation cannot automatically be applied to another.
Movement Through the Mouth Tissue Is Another Challenge
The oral mucosa is accessible, but it is still a biological barrier. A product must move through layers of cells and surrounding material before it can reach underlying blood vessels.
Researchers describe two broad movement pathways:
- Transcellular movement, which passes through cells.
- Paracellular movement, which passes between cells.
Programs are often larger and more water-loving than many small molecules. These properties can make it difficult for them to cross cell membranes. Saliva can also dilute the material, while tongue movement, swallowing, eating, and speaking can reduce contact time.
Research systems may explore:
- Mucoadhesive materials that help maintain contact with the tissue.
- Protective matrices that help limit breakdown.
- Permeation-enhancing components that may support movement across the barrier.
- Films, patches, nanoparticles, or other carrier systems.
- Testing methods that measure dissolution, tissue contact, stability, and transport.
These approaches remain subjects of formulation and delivery research. A permeation enhancer is not automatically beneficial in every formulation. Researchers must consider tissue compatibility, local irritation, consistency, and whether the intended transport can be measured reliably.
What Researchers Are Exploring About Needle-Free Convenience
Needle-free delivery is an important area of interest because the delivery format can affect convenience and consistency. Researchers are exploring whether thin oral strips and other mucosal systems can reduce some of the physical barriers associated with injection-based research formats.
Potential convenience questions include:
- Can a format be portable and travel-friendly?
- Can it dissolve without water?
- Can it simplify handling in research settings?
- Can the formulation maintain quality during ordinary handling?
- Can the delivery process be made simpler while still allowing reliable measurement and documentation?
Convenience, however, is not the same as proof of effectiveness. A needle-free format is not automatically safer, more effective, approved, or appropriate for human use. It is a different delivery approach that requires careful research and documentation.
You can learn more about VIP New Life’s research-focused offerings through our Research Products, review applicable documentation in our COA Library, and explore general product information through our Frequently Asked Questions.
A Clear Research Perspective
Buccal delivery is not one simple event. It involves a sequence of scientific questions:
- Will the product remain stable?
- Will it remain near the mucosal tissue?
- Can it move through the tissue barrier?
- Can the process be measured consistently?
- Does the result apply only to a specific formulation, or can it be repeated?
These questions help explain why responsible education matters. The words “oral,” “dissolving,” and “needle-free” describe a format or route. They do not, by themselves, establish absorption, biological activity, approval, or human suitability.
VIP New Life is committed to helping you review research with clarity, transparency, and appropriate boundaries.
Follow the Needle-Free Education Series
This article supports our ongoing Needle-Free Education Series. We are continuing to share simple explanations of buccal delivery, stability, mucosal barriers, and research considerations.
You can follow the series on our official Instagram page and Facebook page.
Whether you are beginning to learn about research or looking for a clearer explanation of delivery technology, we encourage you to review reliable sources, ask informed questions, and move forward carefully.
Research Use Only Notice
Applicable VIP New Life research products are intended strictly for laboratory research purposes only. They are not intended for human consumption, self-administration, diagnosis, treatment, cure, or prevention of any disease. This article is educational and does not provide dosing instructions, protocols, treatment recommendations, or medical advice.
Research and Further Reading
- A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods, DARU Journal of Pharmaceutical Sciences.
- An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems, Pharmaceutics.
- Enhancing the buccal mucosal delivery of protein therapeutics, Pharmaceutical Research.
- Recent Progress in the Oral Delivery of Therapeutic Programs and Proteins, Advanced Pharmaceutical Bulletin.
- Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 drugs, Molecular Pharmaceutics.
Retatrutide has drawn a lot of attention in research and wellness conversations. Many headlines focus on big early findings, but it helps to slow down and look at what the studies actually say.
In simple terms, retatrutide is an investigational molecule being studied because it interacts with three important signaling pathways in the body: GLP-1, GIP, and glucagon. That makes it different from compounds that act on only one or two of these pathways.
Research Use Only statement: As of August 2026, retatrutide is not FDA-approved and is not approved for general clinical use. It remains an investigational compound under study. This article is provided for educational purposes and Research Use Only discussion.
What Is Retatrutide?
Retatrutide, also known by the research code LY3437943, is described in published research as a triple receptor agonist.
That phrase sounds technical, but the basic idea is simple. An agonist is a compound that turns on a receptor. A receptor is like a message receiver in the body. When a receptor is activated, it can change how the body handles signals related to hunger, blood sugar, or energy use.
Retatrutide is being studied because it activates three pathways at the same time:
- GLP-1, or glucagon-like
- GIP, or glucose-dependent insulinotropic
- Glucagon
Researchers are interested in whether combining these three signals in one molecule creates a different metabolic response than working through just one pathway alone.
That does not mean the research proves the same outcome for every person. Clinical trials measure what happens in specific study groups under controlled conditions. They do not provide a personal-use plan.
Why Are Researchers Interested?
Researchers are interested in retatrutide mainly because it works across three pathways instead of one.
The body does not manage hunger, blood sugar, and energy use through a single switch. These systems overlap. That is why researchers want to know what happens when GLP-1, GIP, and glucagon signals are activated together.
Early clinical research has looked at areas such as:
- Body-weight changes
- Blood glucose and HbA1c
- Appetite-related signals
- Liver fat
- Blood lipids
- Visceral and abdominal fat
- Cardiometabolic markers
- Safety and tolerability
One widely discussed study was a 2023 phase 2 trial published in the New England Journal of Medicine. It studied retatrutide in adults with overweight or obesity and reported substantial average body-weight reductions in some study groups over 48 weeks.
That phase 2 study remains important historical context. Since then, the research has moved forward. In May 2026, Lilly reported Phase 3 TRIUMPH-1 topline results. In July 2026, the company also reported positive Phase 3 topline results from TRIUMPH-2 and TRIUMPH-3. These updates show that retatrutide research has advanced into larger late-stage studies, but they do not mean approval has been granted, is close, or is guaranteed. Retatrutide remains investigational and not FDA-approved, and other Phase 3 and longer-term studies are still ongoing.
Read the published phase 2 obesity study in the New England Journal of Medicine.
Understanding the GLP-1, GIP, and Glucagon Combination
GLP-1: A Signal Linked to Fullness and Blood Sugar
GLP-1 is a natural hormone your body makes, especially after you eat. In simple terms, it helps the body send messages related to feeling full and handling blood sugar after meals.
Researchers often study GLP-1 in connection with:
- Appetite signals
- Insulin release when glucose is present
- How quickly food moves through the stomach
- Blood sugar regulation after eating
If the phrase glucose-dependent sounds overly technical, it simply means the signal is influenced by glucose levels rather than acting the same way at all times.
GIP: A Signal That Helps the Body Respond to Food
GIP is another natural hormone released after eating. It is part of the body’s built-in meal-response system.
Researchers study GIP in relation to:
- Insulin response after meals
- How the body handles nutrients
- Energy storage and energy use
- How it works alongside GLP-1
GIP is not just a copy of GLP-1. It has its own job and its own receptor, which is one reason researchers are interested in combining the two signals.
Glucagon: A Signal Related to Stored Energy
Glucagon is another natural hormone. It is often described as helping the body access stored energy.
In retatrutide research, scientists are looking at whether glucagon receptor activity may be related to:
- Energy release
- Fat metabolism
- Energy expenditure
- Liver fat regulation
This is also why retatrutide is not best described as simply a “stronger GLP-1.” It is better understood as a molecule designed to activate three different but connected signals.
What Makes Retatrutide Different?
What makes retatrutide stand out in research is its three-part design.
Some compounds are studied for one signaling pathway. Others are studied for two. Retatrutide is being studied for three: GLP-1, GIP, and glucagon.
That leads researchers to a broader question:
> What happens when several metabolic signals are activated together?
That question matters because metabolism is influenced by many factors, not just one. Hunger, blood sugar, energy use, sleep, stress, activity, and individual biology can all affect what researchers observe.
It is also important to stay balanced. More pathways do not automatically mean a better outcome. They simply create a different and more complex research picture.
What Has the Research Reported So Far?
Published research and company-reported topline updates have now reported findings in several areas.
As historical context, phase 2 research drew much of the early attention. In an obesity study, researchers observed significant average body-weight changes over the study period. They also looked at measurements such as waist circumference, blood pressure, blood glucose, and blood lipids.
A separate phase 2 trial in adults with type 2 diabetes examined HbA1c and body-weight changes. HbA1c is a common lab marker that reflects average blood sugar over time. In that study, several retatrutide groups showed improvements in these measured outcomes compared with placebo. Reported adverse events included gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation.
Researchers have also studied retatrutide in metabolic dysfunction-associated steatotic liver disease, or MASLD, a condition involving excess fat in the liver. In that study, magnetic resonance imaging, or MRI, was used to measure liver fat. The study reported reductions in liver fat along with changes in other metabolic measurements.
More recently, Lilly reported Phase 3 topline results from TRIUMPH-1 in May 2026 and positive topline results from TRIUMPH-2 and TRIUMPH-3 in July 2026. These are sponsor-reported updates from larger studies, which is different from peer-reviewed published journal research. They are important to follow, but they should still be read carefully and in context.
These findings are scientifically important, but they are still research findings. They do not mean retatrutide is approved to treat obesity, type 2 diabetes, liver disease, or any other condition. More research is still needed, especially on long-term outcomes.
Review the published MASLD study in Nature Medicine.
What Is Still Unknown?
Current research has reported notable findings in several areas, but important questions remain.
Researchers are still studying:
- Long-term safety over multiple years
- Rare or delayed adverse events
- How long observed changes last
- What happens after discontinuation
- Effects in different populations
- Cardiovascular and kidney outcomes
- Lean mass and body-composition changes
- Long-term liver outcomes
- Why some people may respond differently than others
Phase 2 studies helped identify early patterns. Several Phase 3 TRIUMPH studies have now reported topline results, while additional retatrutide Phase 3 and longer-term studies continue to evaluate other populations, outcomes, safety questions, durability, and longer-term effects.
Phase 3 results do not mean regulatory approval has been granted, is close, or is guaranteed. Retatrutide remains investigational and is not currently FDA-approved. Trial information and study status can be reviewed through ClinicalTrials.gov and sponsor materials.
Research Use Only: What That Means
Research Use Only, or RUO, refers to the intended status and use of applicable research products.
This article is an educational discussion of published research and company-reported study updates. It is meant to help you understand what researchers are studying, what has been reported so far, and what still remains uncertain.
It does not provide dosing, protocols, treatment recommendations, medical advice, or permission for human use.
VIP New Life does not diagnose, treat, prescribe, recommend dosing, or provide medical advice. All applicable research products are intended for laboratory research purposes only. They are not intended for human consumption or for the diagnosis, treatment, cure, or prevention of any disease.
Transparency Supports Informed Decisions
Clear documentation helps researchers and customers understand what a product is intended for and what information is available.
You can also explore:
A Certificate of Analysis, or COA, may provide information such as product identity, purity, batch details, and testing documentation for applicable research products. Reviewing documentation is one way to support responsible research and informed decisions. A COA does not change a product’s Research Use Only status or establish approval for human use.
Beyond the Headlines
The most balanced way to understand retatrutide is to keep two ideas in mind at the same time.
First, the research is meaningful. A single molecule that interacts with GLP-1, GIP, and glucagon gives researchers a way to study several connected metabolic signals together.
Second, there is still a great deal to learn. Retatrutide is investigational, not FDA-approved, and still being studied. Early results can help guide future research, but they do not answer every question.
At VIP New Life, our goal is to make complex topics easier to understand. We believe informed decisions begin with education, transparency, responsible research, and ongoing support.
For additional discussion, VIP New Life is also covering this subject through our “Retatrutide: Beyond the Headlines” educational series on social media. Follow along on Instagram and Facebook.
Research and Further Reading
Peer-reviewed published research
- Phase 2 obesity study in the New England Journal of Medicine
- Phase 2 type 2 diabetes study on PubMed
- MASLD study in Nature Medicine
Sponsor-reported Phase 3 topline results
Trial registry information
Important notice: This article is for general education and research use only. Retatrutide is investigational and is not currently FDA-approved. Nothing in this article is medical advice, a diagnosis, a treatment recommendation, a prescription, a dosing instruction, or a claim that retatrutide diagnoses, treats, cures, or prevents any disease. Applicable research products are intended for laboratory research purposes only and are not intended for human consumption.
